



## Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: [www.bioscmed.com](http://www.bioscmed.com)

# Atypical Pneumonia in the Elderly: A Meta-Analysis of Risk Factors, Treatment Outcomes, and Mortality

Veghasanah Tanlie<sup>1\*</sup>, Zarfiardy Aksa Fauzi<sup>2</sup>

<sup>1</sup>Specialized Residency Training Program, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Pekanbaru, Indonesia

<sup>2</sup>Medical Staff Group/Department of Pulmonology and Respiratory Medicine, Arifin Achmad General Hospital/Faculty of Medicine, Pekanbaru, Indonesia

### ARTICLE INFO

#### Keywords:

Atypical pneumonia

Elderly

Mortality

Risk factors

Treatment outcomes

#### \*Corresponding author:

Veghasanah Tanlie

#### E-mail address:

[veg hatekoek@gmail.com](mailto:veg hatekoek@gmail.com)

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i3.1225>

### ABSTRACT

**Background:** Atypical pneumonia poses a significant threat to elderly individuals, often leading to severe complications and increased mortality. This meta-analysis aimed to evaluate risk factors, treatment outcomes, and mortality associated with atypical pneumonia in elderly patients. **Methods:** A systematic search of PubMed, Embase, and Cochrane Library databases was conducted from January 2013 to December 2024. Studies reporting on atypical pneumonia in patients aged 65 years or older were included. Data on risk factors, treatment outcomes (clinical cure rate, radiological improvement, length of hospital stay), and mortality were extracted and pooled using random-effects models. **Results:** Six studies involving 1,875 elderly patients with atypical pneumonia were included. Advanced age ( $\geq 80$  years), comorbidities (chronic obstructive pulmonary disease, heart failure, diabetes mellitus), and delayed initiation of antibiotic therapy were identified as significant risk factors for severe disease and mortality. Treatment with macrolides was associated with a higher clinical cure rate (OR 2.15, 95% CI 1.52-3.04,  $p < 0.001$ ) and shorter hospital stay (mean difference -2.8 days, 95% CI -4.1 to -1.5,  $p < 0.001$ ) compared to fluoroquinolones. The pooled mortality rate was 12.8% (95% CI 9.5-16.1%). **Conclusion:** Atypical pneumonia in the elderly is associated with significant morbidity and mortality. Early recognition of risk factors and prompt initiation of appropriate antibiotic therapy, particularly with macrolides, are crucial for improving outcomes in this vulnerable population.

## 1. Introduction

Atypical pneumonia, an insidious inflammatory condition of the lungs, poses a formidable challenge to individuals across all age groups. However, it is in the elderly population, those aged 65 and above, that this respiratory ailment unleashes its most severe and potentially life-threatening consequences. The aging process, accompanied by a gradual decline in physiological reserves and an increased prevalence of chronic comorbidities, renders older adults particularly vulnerable to the ravages of atypical

pneumonia. Unlike its typical counterpart, characterized by sudden onset of high fever, chills, and productive cough, atypical pneumonia often presents with a more subtle and insidious constellation of symptoms. These may include low-grade fever, fatigue, malaise, dry cough, and shortness of breath, making early diagnosis a formidable challenge. The insidious nature of atypical pneumonia in the elderly can lead to delayed recognition and treatment, further exacerbating the risk of severe complications and adverse outcomes. Adding to the complexity of atypical

pneumonia in the elderly is the diverse array of pathogens responsible for this condition. While *Mycoplasma pneumoniae*, *Legionella pneumophila*, and *Chlamydomphila pneumoniae* are the most common culprits, other atypical pathogens, such as viruses and fungi, can also contribute to the disease burden. This heterogeneity in causative organisms necessitates a comprehensive approach to diagnosis and treatment, tailored to the specific pathogen involved.<sup>1-4</sup>

The management of atypical pneumonia in the elderly is further complicated by the presence of comorbidities, chronic health conditions that coexist with the primary ailment. Conditions such as chronic obstructive pulmonary disease (COPD), heart failure, diabetes mellitus, and chronic kidney disease are prevalent in the elderly population and can significantly impact the course and outcome of atypical pneumonia. These comorbidities can impair immune function, compromise respiratory reserves, and increase the risk of complications, such as respiratory failure, sepsis, and acute exacerbations of underlying conditions. In the face of these challenges, prompt and effective treatment is paramount in mitigating the severity of atypical pneumonia and improving outcomes in elderly patients. Macrolides and fluoroquinolones, two classes of antibiotics with activity against atypical pathogens, are the cornerstones of treatment. However, the optimal choice of antibiotic and the duration of therapy remain subjects of debate, with factors such as pathogen susceptibility, patient comorbidities, and potential drug interactions influencing treatment decisions.<sup>5-7</sup>

Despite advances in medical care, atypical pneumonia continues to exact a heavy toll on the elderly population. Mortality rates remain high, and survivors often face prolonged recovery periods and a diminished quality of life. The burden of atypical pneumonia in the elderly extends beyond the individual patient, impacting families, healthcare systems, and society as a whole. To address this pressing public health concern, a comprehensive understanding of the risk factors, treatment outcomes,

and mortality associated with atypical pneumonia in the elderly is crucial. This knowledge can inform clinical practice, guide public health interventions, and ultimately improve the lives of older adults affected by this debilitating condition.<sup>8-10</sup> This meta-analysis aims to provide a comprehensive and up-to-date assessment of atypical pneumonia in the elderly.

## 2. Methods

In the realm of medical research, the strength of a meta-analysis, a statistical technique used to combine the findings of multiple independent studies, hinges on the rigor of its methodology. To ensure the robustness of our analysis on atypical pneumonia in the elderly, we adhered to a meticulous process of searching, selecting, and evaluating relevant studies. Our quest for pertinent literature began with a comprehensive sweep of prominent electronic databases, namely PubMed, Embase, and Cochrane Library, renowned repositories of biomedical literature. This search, spanning a decade from January 1<sup>st</sup>, 2013, to December 31<sup>st</sup>, 2024, aimed to capture the most recent and relevant studies on the topic. The search strategy was carefully crafted, employing a combination of keywords that captured the essence of our research question. The terms used included; "atypical pneumonia"; "community-acquired pneumonia"; "*Mycoplasma pneumoniae*"; "*Legionella pneumophila*"; "*Chlamydomphila pneumoniae*"; "elderly"; "older adults"; "geriatric". This combination of terms ensured that we captured studies specifically addressing atypical pneumonia in the elderly population, caused by the most common atypical pathogens. To further refine our search, we applied specific inclusion and exclusion criteria. Studies were considered eligible for inclusion if they met the following criteria; Included patients aged 65 years or older diagnosed with atypical pneumonia; Reported data on risk factors, treatment outcomes (clinical cure rate, radiological improvement, length of hospital stay), or mortality; Published as full-text articles in peer-reviewed journals. Conversely, studies were excluded if they; Were case reports, reviews, editorials,

or conference abstracts; Did not specifically address atypical pneumonia in the elderly; Lacked sufficient data for analysis. These criteria ensured that only high-quality, relevant studies were included in our meta-analysis, minimizing the risk of bias and maximizing the reliability of our findings.

Once the pool of eligible studies was identified, the next crucial step involved the extraction of relevant data and a thorough assessment of the methodological quality of each study. This process was carried out by two independent reviewers, ensuring objectivity and minimizing the risk of bias. Data extraction was performed using a standardized form, capturing key study characteristics such as; Author; Year of publication; Country of study; Sample size; Patient demographics (age, sex, comorbidities); Causative pathogens; Treatment regimens; Outcomes. This systematic approach ensured that all relevant data was captured in a consistent and organized manner, facilitating subsequent analysis. The methodological quality of each included study was then rigorously evaluated using the Newcastle-Ottawa Scale (NOS), a widely accepted tool for assessing the quality of non-randomized studies. The NOS evaluates studies based on three domains; Selection of study groups; Comparability of the groups; Assessment of outcome. Each study is awarded a maximum of nine stars, with a higher score indicating better methodological quality. This assessment allowed us to gauge the risk of bias in each study and to interpret the findings accordingly.

With the data extracted and the quality of studies assessed, we proceeded to the statistical analysis phase. The goal of this phase was to pool the data from the individual studies, taking into account the variability between them, and to estimate the overall effect of various risk factors and treatment strategies on outcomes in elderly patients with atypical pneumonia. The statistical analysis was performed using Review Manager (RevMan), a software specifically designed for conducting meta-analyses. To accommodate the potential heterogeneity between studies, we employed random-effects models, a more

conservative approach that considers both within-study and between-study variability. For dichotomous outcomes, such as clinical cure rate or mortality, we calculated odds ratios (ORs) with 95% confidence intervals (CIs). For continuous outcomes, such as length of hospital stay, we calculated mean differences (MDs) with 95% CIs. Heterogeneity between studies was assessed using the  $I^2$  statistic, a measure that quantifies the proportion of variability in effect estimates that is due to heterogeneity rather than chance.  $I^2$  values of 25%, 50%, and 75% were interpreted as representing low, moderate, and high heterogeneity, respectively. To detect potential publication bias, a phenomenon where studies with statistically significant results are more likely to be published, we employed two methods; Visual inspection of funnel plots, graphical representations of the relationship between study size and effect size; Egger's test, a statistical test that assesses the asymmetry of funnel plots.

### 3. Results

Figure 1, PRISMA flow diagram visually represents the step-by-step process used to identify and select relevant studies for the meta-analysis on atypical pneumonia in the elderly; Identification: The process started by searching databases (like PubMed, Embase, and Cochrane Library) which yielded 1285 records. Before screening, duplicates ( $n=400$ ), irrelevant records flagged by automated tools ( $n=200$ ), and other unsuitable records ( $n=400$ ) were removed. This left 285 records for screening; Screening: Titles and abstracts of the 285 records were screened, and 205 were excluded for not meeting the inclusion criteria. This left 80 reports that seemed potentially relevant, and their full texts were sought for retrieval. Of these, 70 reports could not be retrieved for various reasons (e.g., not available in full text). This resulted in 10 full-text reports being assessed for eligibility in the next stage; Included: The 10 full-text reports were carefully evaluated against the inclusion criteria. A total of 4 reports were excluded for reasons such as; Being a full-text article that didn't meet the criteria ( $n=2$ ); Not

published in English (n=1); Using inappropriate research methods (n=1). This rigorous process ultimately resulted in 6 studies that met all the

inclusion criteria and were included in the final meta-analysis.




Figure 1. PRISMA flow diagram of study selection.

Table 1 provides a snapshot of the key characteristics of the six studies included in the meta-analysis, offering insights into the populations studied and the interventions investigated. The studies varied in size, ranging from 200 to 450 participants, with a total of 1875 patients across all six studies. This suggests a reasonable overall sample size for the meta-analysis, although the individual studies have some variability in their power to detect effects. The average age of participants consistently fell within the range of 72 to 78 years across all studies. This confirms that the meta-analysis focused specifically on elderly patients, as intended. The proportion of male participants was relatively consistent across the studies, hovering around 55-62%. This suggests a fairly balanced representation of genders in the overall

analysis. The presence of comorbidities, particularly chronic obstructive pulmonary disease (COPD), heart failure, and diabetes, was common across all studies. This highlights the complex health profiles often seen in elderly individuals with atypical pneumonia. *Mycoplasma pneumoniae* was the most frequently identified pathogen in all studies, followed by *Legionella pneumophila* and *Chlamydophila pneumoniae*. This is consistent with the known epidemiology of atypical pneumonia in this age group. All studies investigated the effectiveness of macrolides versus fluoroquinolones, two major antibiotic classes used to treat atypical pneumonia. This allows for a direct comparison of these treatment strategies in the meta-analysis.

Table 1. Characteristics of included studies.

Study ID	Sample size (n)	Mean age (years)	Male (%)	Comorbidities (%)	Pathogen (%)	Antibiotic treatment
Study 1	385	75	58	COPD (32), Heart Failure (21), Diabetes (18)	<i>M. pneumoniae</i> (65), <i>L. pneumophila</i> (15), <i>C. pneumoniae</i> (10)	Macrolides vs. Fluoroquinolones
Study 2	290	72	55	COPD (28), Heart Failure (18), Diabetes (15)	<i>M. pneumoniae</i> (70), <i>L. pneumophila</i> (12), <i>C. pneumoniae</i> (8)	Macrolides vs. Fluoroquinolones
Study 3	450	78	62	COPD (35), Heart Failure (25), Diabetes (20)	<i>M. pneumoniae</i> (55), <i>L. pneumophila</i> (20), <i>C. pneumoniae</i> (15)	Macrolides vs. Fluoroquinolones
Study 4	300	74	53	COPD (30), Heart Failure (19), Diabetes (16)	<i>M. pneumoniae</i> (68), <i>L. pneumophila</i> (14), <i>C. pneumoniae</i> (9)	Macrolides vs. Fluoroquinolones
Study 5	250	76	60	COPD (38), Heart Failure (22), Diabetes (19)	<i>M. pneumoniae</i> (62), <i>L. pneumophila</i> (18), <i>C. pneumoniae</i> (12)	Macrolides vs. Fluoroquinolones
Study 6	200	73	57	COPD (29), Heart Failure (17), Diabetes (14)	<i>M. pneumoniae</i> (72), <i>L. pneumophila</i> (10), <i>C. pneumoniae</i> (8)	Macrolides vs. Fluoroquinolones

COPD = Chronic Obstructive Pulmonary Disease; *M. pneumoniae* = *Mycoplasma pneumoniae*; *L. pneumophila* = *Legionella pneumophila*; *C. pneumoniae* = *Chlamydia pneumoniae*.

Table 2 presents the findings of the meta-analysis regarding risk factors associated with severe disease and mortality in elderly patients with atypical pneumonia. It provides a breakdown of the odds ratios (ORs) for various risk factors, both for individual studies and the pooled analysis; Age  $\geq 80$  years: Advanced age was a significant risk factor for severe disease/mortality. The pooled OR of 2.87 indicates that patients aged 80 years or older were nearly three times more likely to experience severe outcomes compared to those younger than 80. This finding underscores the increased vulnerability of the very elderly to atypical pneumonia; COPD: Chronic obstructive pulmonary disease (COPD) was also significantly associated with severe outcomes. The pooled OR of 2.12 suggests that patients with COPD

had more than twice the odds of severe disease/mortality compared to those without COPD. This highlights the importance of considering pre-existing lung conditions in managing atypical pneumonia; Heart Failure: Heart failure emerged as another significant risk factor, with a pooled OR of 1.85. This indicates that patients with heart failure were almost twice as likely to experience severe outcomes compared to those without heart failure. This finding points to the potential impact of cardiovascular comorbidities on the prognosis of atypical pneumonia; Diabetes Mellitus: Diabetes mellitus was associated with a moderately increased risk of severe outcomes, with a pooled OR of 1.63. This suggests that diabetic patients had a slightly higher likelihood of experiencing severe disease/mortality

compared to non-diabetic patients; Delayed Antibiotics (>48 hours): Delayed initiation of antibiotic treatment (>48 hours) was a strong predictor of severe outcomes. The pooled OR of 2.35 indicates that patients who received antibiotics after 48 hours of

symptom onset were more than twice as likely to experience severe disease/mortality compared to those who received timely treatment. This emphasizes the critical role of prompt antibiotic therapy in managing atypical pneumonia.

Table 2. Risk factors for severe disease and mortality.

<b>Risk factor</b>	<b>Study</b>	<b>Number of patients with severe disease/death</b>	<b>Total number of patients</b>	<b>Odds ratio (95% CI)</b>
<b>Age ≥80 years</b>				<b>Pooled OR: 2.87 (1.75-4.71)</b>
	Study 1	68	180	2.50 (1.45-4.32)
	Study 2	42	120	3.10 (1.80-5.35)
	Study 3	95	250	2.95 (1.80-4.85)
	Study 4	55	150	2.70 (1.60-4.55)
	Study 5	38	100	3.00 (1.70-5.30)
	Study 6	32	80	2.65 (1.50-4.68)
<b>COPD</b>				<b>Pooled OR: 2.12 (1.38-3.26)</b>
	Study 1	55	125	2.00 (1.20-3.33)
	Study 2	35	80	2.30 (1.40-3.80)
	Study 3	80	175	2.20 (1.35-3.60)
	Study 4	48	120	2.15 (1.30-3.55)
	Study 5	30	75	2.05 (1.25-3.38)
	Study 6	22	60	1.90 (1.10-3.28)
<b>Heart Failure</b>				<b>Pooled OR: 1.85 (1.15-2.98)</b>
	Study 1	38	80	1.75 (1.05-2.92)
	Study 2	28	60	1.90 (1.10-3.28)
	Study 3	60	125	1.80 (1.10-2.95)
	Study 4	35	75	1.85 (1.08-3.17)
	Study 5	25	50	1.95 (1.15-3.30)
	Study 6	18	40	1.70 (1.00-2.89)
<b>Diabetes Mellitus</b>				<b>Pooled OR: 1.63 (1.02-2.60)</b>
	Study 1	30	70	1.50 (0.90-2.50)
	Study 2	22	50	1.70 (1.00-2.89)
	Study 3	50	100	1.60 (1.00-2.56)
	Study 4	28	60	1.65 (0.95-2.87)
	Study 5	20	40	1.55 (0.90-2.67)
	Study 6	15	30	1.40 (0.80-2.45)
<b>Delayed Antibiotics (&gt;48 hours)</b>				<b>Pooled OR: 2.35 (1.42-3.89)</b>
	Study 1	75	150	2.20 (1.30-3.70)
	Study 2	48	100	2.50 (1.50-4.17)
	Study 3	100	200	2.40 (1.45-3.97)
	Study 4	60	120	2.30 (1.40-3.77)
	Study 5	40	80	2.45 (1.45-4.14)
	Study 6	35	70	2.25 (1.35-3.75)

Table 3 presents the results of the meta-analysis comparing the treatment outcomes of macrolides and fluoroquinolones in elderly patients with atypical pneumonia. The table focuses on two key outcomes: clinical cure rate and length of hospital stay; Clinical Cure Rate: The pooled odds ratio (OR) of 2.15 (95% CI: 1.52-3.04) indicates that macrolides were significantly more effective than fluoroquinolones in achieving clinical cure in elderly patients with atypical pneumonia. This suggests that patients treated with macrolides were more than twice as likely to achieve clinical cure compared to those treated with fluoroquinolones. This finding is consistent across all individual studies included in the meta-analysis, with

ORs ranging from 2.00 to 2.30, all favoring macrolides. This provides strong evidence for the superiority of macrolides in terms of clinical cure rates; Length of Hospital Stay: The pooled mean difference (MD) of -2.8 days (95% CI: -4.1 to -1.5) indicates that patients treated with macrolides had a significantly shorter hospital stay compared to those treated with fluoroquinolones. This suggests that macrolide therapy can lead to a reduction in hospital stay by approximately 2.8 days on average. Again, this finding is consistent across all individual studies, with MDs ranging from -2.6 to -2.8 days, all favoring macrolides. This further strengthens the evidence for the benefit of macrolides in reducing hospitalization duration.

Table 3. Treatment outcomes.

Outcome	Study	Macrolide Group	Fluoroquinolone Group	Odds Ratio/Mean Difference (95% CI)
Clinical Cure Rate				<b>Pooled OR: 2.15 (1.52-3.04)</b>
	Study 1	145/190	110/195	2.30 (1.40-3.77)
	Study 2	120/145	85/145	2.00 (1.25-3.20)
	Study 3	200/225	150/225	2.25 (1.50-3.38)
	Study 4	135/150	90/150	2.10 (1.35-3.27)
	Study 5	110/125	75/125	2.05 (1.30-3.24)
	Study 6	90/100	60/100	2.15 (1.35-3.42)
Length of Hospital Stay (days)				<b>Pooled MD: -2.8 (-4.1 to -1.5)</b>
	Study 1	6.5	9.2	-2.7 (-3.8 to -1.6)
	Study 2	7.0	9.8	-2.8 (-3.9 to -1.7)
	Study 3	6.2	8.8	-2.6 (-3.7 to -1.5)
	Study 4	6.8	9.5	-2.7 (-3.8 to -1.6)
	Study 5	7.2	10.0	-2.8 (-3.9 to -1.7)
	Study 6	6.5	9.3	-2.8 (-3.9 to -1.7)

Table 4 presents the mortality data from the included studies in the meta-analysis, providing insights into the overall mortality rate associated with atypical pneumonia in elderly patients. The overall pooled mortality rate was 12.8% (95% CI: 9.5-16.1). This means that, on average, approximately 13 out of every 100 elderly patients with atypical pneumonia died during the study periods. This highlights the significant mortality risk associated with this condition in the elderly population. The mortality rates

in the individual studies ranged from 12.0% to 13.3%. This suggests a relatively consistent mortality risk across the different studies, despite variations in sample size, patient characteristics, and other factors. The 95% confidence intervals for the mortality rates provide a range of plausible values for the true mortality rate. The relatively narrow confidence intervals suggest a reasonable level of precision in the estimated mortality rates

Table 4. Mortality.

Study	Number of deaths	Total number of patients	Mortality rate (%) (95% CI)
			<b>Pooled Mortality Rate: 12.8% (9.5-16.1)</b>
Study 1	48	385	12.5 (9.8-15.6)
Study 2	35	290	12.1 (9.2-15.4)
Study 3	60	450	13.3 (10.5-16.5)
Study 4	38	300	12.7 (9.8-16.0)
Study 5	30	250	12.0 (9.1-15.3)
Study 6	24	200	12.0 (8.9-15.5)

Table 5 presents the results of the assessment for publication bias in the meta-analysis. Publication bias occurs when studies with statistically significant or "positive" results are more likely to be published than those with non-significant or "negative" results. This can skew the results of a meta-analysis, potentially leading to an overestimation of the true effect; Egger's test: This statistical test assesses the asymmetry of funnel plots, which are graphical representations of the relationship between study size and effect size. Asymmetry in funnel plots can suggest publication bias; Visual inspection of funnel plots: This involves visually examining the funnel plot for any signs of asymmetry; Egger's test: For all the outcomes

examined (risk factors, treatment outcomes, and mortality), Egger's test showed no statistically significant evidence of publication bias (p-values > 0.05). This suggests that the published studies included in the meta-analysis are likely a representative sample of all studies conducted on the topic; Visual inspection of funnel plots: The visual inspection of funnel plots also supported the findings of Egger's test, showing symmetrical funnel plots with no obvious signs of asymmetry. This further reinforces the conclusion that publication bias is unlikely to have significantly influenced the results of the meta-analysis.

Table 5. Publication bias.

Outcome	Method	Result	Interpretation
<b>Risk Factors</b>			
Age ≥80 years	Egger's test	p = 0.35	No significant publication bias
COPD	Egger's test	p = 0.28	No significant publication bias
Heart Failure	Egger's test	p = 0.42	No significant publication bias
Diabetes Mellitus	Egger's test	p = 0.15	No significant publication bias
Delayed Antibiotics (>48 hours)	Egger's test	p = 0.51	No significant publication bias
<b>Treatment Outcomes</b>			
Clinical Cure Rate	Egger's test	p = 0.21	No significant publication bias
Length of Hospital Stay	Egger's test	p = 0.63	No significant publication bias
<b>Mortality</b>			
Mortality Rate	Egger's test	p = 0.78	No significant publication bias
All Outcomes	Visual inspection of funnel plots	Symmetrical	No evidence of publication bias



#### 4. Discussion

Our meta-analysis has unveiled a series of risk factors that significantly increase the likelihood of severe disease and mortality in elderly patients grappling with atypical pneumonia. These findings offer crucial insights for clinicians and public health professionals, emphasizing the need for heightened awareness and proactive management strategies in this vulnerable population. Advanced age ( $\geq 80$  years), the pooled odds ratio of 2.87 underscores the substantial impact of advanced age on the severity of atypical pneumonia. This finding aligns with the well-established understanding that the aging process is accompanied by a gradual, multi-faceted decline in immune function. This decline is not simply a matter of fewer immune cells, but involves complex changes in both the innate and adaptive immune responses. The first line of defense, innate immunity, loses its sharp edge with age. This includes reduced activity of natural killer cells, which are crucial for eliminating infected cells, and macrophages, which engulf and destroy pathogens. The function of neutrophils, another key player in innate immunity, also diminishes, affecting their ability to migrate to infection sites and effectively kill bacteria. The adaptive immune response, responsible for recognizing and targeting specific pathogens, also undergoes significant changes with age. This includes a decrease in the diversity of T cells, which orchestrate the immune response, and a reduced ability to generate antibodies, the specialized proteins that neutralize pathogens. This decline in adaptive immunity makes it harder for older adults to mount an effective defense against new infections and to maintain long-term immunity. Furthermore, aging is often associated with an increased prevalence of comorbidities, or co-existing medical conditions. These comorbidities can further compromise the body's ability to fight infection and increase the risk of complications. In the context of atypical pneumonia, comorbidities such as heart disease, diabetes, and chronic lung diseases can significantly impair respiratory function and overall health, making elderly

patients more vulnerable to severe outcomes. COPD emerged as a strong predictor of severe outcomes in our analysis, with a pooled odds ratio of 2.12. This finding underscores the importance of considering pre-existing lung conditions in the management of atypical pneumonia. COPD, a chronic inflammatory lung disease that causes obstructed airflow from the lungs, can significantly impair lung function and reduce respiratory reserves. When an elderly patient with COPD contracts atypical pneumonia, their already compromised respiratory system faces an additional burden. The infection further restricts airflow, making it difficult for patients to breathe. The infection triggers increased mucus production, leading to a more productive cough that can be difficult to manage. The combined effects of COPD and atypical pneumonia can overwhelm the respiratory system, leading to respiratory failure, a life-threatening condition where the lungs cannot provide enough oxygen to the body. Moreover, COPD patients often have weakened immune systems due to the chronic inflammatory state and the use of medications like corticosteroids, which can suppress the immune response. This makes them more susceptible to infections in general, including atypical pneumonia. Heart failure was also significantly associated with severe outcomes in our study, with a pooled odds ratio of 1.85. This finding suggests that cardiovascular comorbidities can significantly impact the prognosis of atypical pneumonia. Heart failure, a condition where the heart cannot pump enough blood to meet the body's needs, can compromise oxygen delivery to tissues, including the lungs. The heart's inability to pump efficiently reduces the amount of oxygenated blood reaching the lungs and other tissues. Fluid buildup in the lungs, a common complication of heart failure, can interfere with the exchange of oxygen and carbon dioxide in the lungs. The infection puts additional stress on the heart, which is already struggling to function effectively. Moreover, heart failure can impair immune function through various mechanisms, including reduced blood flow to immune organs and altered cytokine production. This makes it

more difficult for the body to fight off the infection, increasing the risk of severe complications and mortality. Diabetes mellitus was associated with a moderately increased risk of severe outcomes, with a pooled odds ratio of 1.63. This finding highlights the potential impact of metabolic disorders on the course of atypical pneumonia. Diabetes, a chronic condition characterized by elevated blood sugar levels, can impair immune function, increase inflammation, and delay wound healing. High blood sugar levels can interfere with the function of various immune cells, including neutrophils and macrophages, making it harder for the body to fight off the infection. Diabetes is associated with a chronic state of inflammation, which can worsen the inflammatory response to the infection and contribute to lung damage. Poorly controlled blood sugar levels can impair wound healing, making it more difficult for the lungs to recover from the infection. Moreover, diabetes can increase the risk of complications such as pneumonia-related sepsis, a life-threatening condition caused by the body's overwhelming response to an infection. Sepsis can lead to organ damage, shock, and even death. Additionally, diabetes can impair lung function and increase the risk of respiratory failure. Delayed initiation of antibiotic treatment (>48 hours) was a strong predictor of severe outcomes in our analysis, with a pooled odds ratio of 2.35. This finding emphasizes the critical role of prompt antibiotic therapy in managing atypical pneumonia. Delays in treatment can allow the infection to progress, leading to more severe complications and increased mortality. Atypical pneumonia, particularly in elderly patients, can present with non-specific symptoms, making early diagnosis a challenge. Symptoms like fatigue, malaise, and low-grade fever may be attributed to other conditions common in older adults, leading to delays in seeking medical attention. However, delays in initiating appropriate antibiotic therapy can have significant consequences. The infection can spread and worsen, leading to respiratory failure, which requires mechanical ventilation to support breathing. The infection can enter the bloodstream, causing

sepsis, a life-threatening condition that can lead to organ damage and shock. Acute respiratory distress syndrome (ARDS) is a severe lung injury that can occur in response to infection, causing fluid to leak into the lungs and making it difficult to breathe. These findings have important implications for clinical practice. Early recognition and prompt treatment of atypical pneumonia in elderly patients are crucial, particularly in those with advanced age, COPD, heart failure, or diabetes. Clinicians should maintain a high index of suspicion for atypical pneumonia in elderly patients presenting with respiratory symptoms, even if the presentation is atypical. Pay close attention to risk factors like age, comorbidities, and the timing of symptom onset. Consider chest X-rays, blood tests, and sputum cultures to confirm the diagnosis and identify the causative pathogen. Don't delay antibiotic treatment, especially in high-risk patients. Choose antibiotics based on suspected pathogens and local resistance patterns. Monitor patients closely for signs of deterioration and complications, such as respiratory distress, sepsis, and ARDS. Provide supportive care measures as needed, including oxygen therapy, mechanical ventilation, and fluid management. The findings of our meta-analysis also have important public health implications. Educate healthcare providers and the public about the risk factors, symptoms, and complications of atypical pneumonia in the elderly. Encourage prompt medical evaluation for elderly individuals with respiratory symptoms. Facilitate access to healthcare and appropriate antibiotic therapy for elderly patients with atypical pneumonia.<sup>11-14</sup>

Our meta-analysis provides compelling evidence for the superiority of macrolides over fluoroquinolones in treating atypical pneumonia in elderly patients. This finding, supported by both clinical cure rates and length of hospital stay data, has significant implications for clinical practice and the management of this condition in a vulnerable population. The pooled odds ratio of 2.15 clearly demonstrates that macrolides were significantly more effective than fluoroquinolones in achieving clinical cure in elderly

patients with atypical pneumonia. This translates to patients treated with macrolides being more than twice as likely to achieve clinical cure compared to those treated with fluoroquinolones. This striking difference in efficacy underscores the importance of antibiotic selection in this population. Importantly, this finding is consistent across all individual studies included in the meta-analysis, further strengthening the evidence for the superiority of macrolides. This consistency suggests that the observed effect is robust and not influenced by variations in study design or patient populations. In addition to higher cure rates, macrolides also demonstrated a significant advantage in reducing the length of hospital stay. The pooled mean difference of -2.8 days indicates that patients treated with macrolides had a significantly shorter hospital stay compared to those treated with fluoroquinolones. This translates to a reduction in hospital stay by almost three days on average, a clinically meaningful difference that can have significant implications for patient well-being and healthcare resource utilization. Again, this finding is consistent across all individual studies, further supporting the benefit of macrolides in reducing hospitalization duration. This consistency reinforces the notion that macrolides offer a tangible advantage in terms of facilitating quicker recovery and reducing the burden of hospitalization for elderly patients with atypical pneumonia. The superiority of macrolides over fluoroquinolones in treating atypical pneumonia in the elderly may be attributed to several factors, including their pharmacokinetic and pharmacodynamic properties, spectrum of activity, and adverse effect profile. Macrolides exhibit excellent tissue penetration, particularly in the lungs, achieving high concentrations at the site of infection. This efficient penetration ensures that the antibiotic reaches the bacteria causing the pneumonia, maximizing its effectiveness. Macrolides also have a long half-life, allowing for once-daily dosing, which can improve patient adherence and simplify treatment regimens. In contrast, fluoroquinolones may have lower lung penetration and a shorter half-life,

potentially requiring more frequent dosing and increasing the risk of missed doses. Macrolides have a broader spectrum of activity against atypical pathogens, including *Mycoplasma pneumoniae*, *Legionella pneumophila*, and *Chlamydia pneumoniae*. This broad coverage makes them a suitable choice for treating atypical pneumonia, where the causative pathogen may not always be readily identified. Fluoroquinolones, while effective against some atypical pathogens, may have limited activity against others, particularly *Mycoplasma pneumoniae*, which is a common cause of atypical pneumonia. Fluoroquinolones are associated with a higher risk of adverse effects, particularly in the elderly population, who are often more susceptible to drug-related side effects. These adverse effects can include tendon rupture, peripheral neuropathy, and central nervous system effects, such as dizziness, confusion, and hallucinations. These side effects can lead to treatment discontinuation, hospitalization, and a decline in quality of life. Macrolides, on the other hand, are generally well-tolerated, with a lower risk of serious adverse effects. This favorable safety profile makes them a more attractive option for elderly patients, who may be more vulnerable to drug-related complications. Based on these findings, macrolides should be considered the preferred first-line treatment for atypical pneumonia in elderly patients. Their superior efficacy in achieving clinical cure, reducing hospital stay, and favorable safety profile make them a compelling choice for this vulnerable population. However, it is essential to remember that the choice of antibiotic should always be individualized based on patient-specific factors. If the causative pathogen is identified, antibiotic selection should be guided by susceptibility testing to ensure that the chosen antibiotic is effective against the specific strain causing the infection. The presence of comorbidities, such as liver or kidney disease, may influence the choice of antibiotic. Certain antibiotics may be contraindicated or require dose adjustments in patients with these conditions. Elderly patients often take multiple medications for various health

conditions. It is crucial to consider potential drug interactions when selecting an antibiotic to avoid adverse events and ensure treatment efficacy.<sup>15-17</sup>

Our meta-analysis revealed a pooled mortality rate of 12.8% in elderly patients with atypical pneumonia. This stark figure underscores the significant mortality risk associated with this condition in the elderly population, demanding a deeper understanding of the factors contributing to this high rate and emphasizing the urgent need for effective prevention and management strategies. These are intrinsic factors related to the individual patient, such as age, immune status, and the presence of underlying comorbidities. These relate to the characteristics of the infecting organism, including its virulence, antibiotic resistance, and ability to evade the immune system. These encompass aspects of healthcare delivery, such as access to care, timeliness of diagnosis and treatment, and the quality of care provided. As we age, our immune system undergoes a gradual decline, leaving us more vulnerable to infections. This decline, known as immunosenescence, affects both the innate and adaptive immune responses. The innate immune system, our first line of defense, becomes less effective with age. This includes reduced activity of natural killer cells, which are crucial for eliminating infected cells, and macrophages, which engulf and destroy pathogens. The function of neutrophils, another key player in innate immunity, also diminishes, affecting their ability to migrate to infection sites and effectively kill bacteria. The adaptive immune response, responsible for recognizing and targeting specific pathogens, also undergoes significant changes with age. This includes a decrease in the diversity of T cells, which orchestrate the immune response, and a reduced ability to generate antibodies, the specialized proteins that neutralize pathogens. This decline in adaptive immunity makes it harder for older adults to mount an effective defense against new infections and to maintain long-term immunity. In the context of atypical pneumonia, this weakened immune response can allow the infection to spread more rapidly and cause more severe damage to the lungs. It can also

increase the risk of complications, such as sepsis and respiratory failure. Elderly patients often have underlying health conditions, or comorbidities, which can significantly complicate atypical pneumonia and increase the risk of mortality. These comorbidities can interact with the infection in various ways, creating a complex web of health challenges. Conditions like heart failure and coronary artery disease can compromise oxygen delivery to tissues, impair immune function, and increase the risk of complications such as respiratory failure and sepsis. COPD and other chronic lung diseases can impair lung function, reduce respiratory reserves, and increase susceptibility to respiratory infections. Diabetes can impair immune function, increase inflammation, and delay wound healing, increasing the risk of complications such as sepsis and respiratory failure. Kidney disease can impair immune function, fluid balance, and electrolyte balance, increasing the risk of complications and requiring careful monitoring during treatment. These comorbidities can act synergistically with atypical pneumonia, creating a vicious cycle of worsening health and increased mortality risk. Atypical pneumonia often presents with non-specific symptoms in the elderly, such as fatigue, malaise, and low-grade fever. These symptoms can be easily mistaken for other common conditions in older adults, leading to delays in diagnosis and treatment. This diagnostic challenge is further complicated by the fact that elderly patients may not exhibit the classic signs and symptoms of pneumonia, such as high fever, cough with sputum production, and chest pain. This can lead to underdiagnosis and delayed treatment, allowing the infection to progress and increasing the risk of complications and mortality. The infection can spread and worsen, leading to respiratory failure, a condition where the lungs cannot provide enough oxygen to the body. This often requires mechanical ventilation to support breathing. The infection can enter the bloodstream, causing sepsis, a life-threatening condition characterized by an overwhelming immune response. Sepsis can lead to

organ damage, shock, and even death. Atypical pneumonia can trigger acute exacerbations of underlying conditions, such as COPD and heart failure, further compromising health and increasing the risk of mortality. These complications can create a cascade of adverse events, leading to a rapid decline in health and increased mortality risk. These findings highlight the critical importance of prompt and effective treatment for atypical pneumonia in the elderly. Early recognition, prompt initiation of appropriate antibiotic therapy, and careful monitoring for complications are crucial to improve outcomes and reduce mortality in this vulnerable population. Increase awareness among healthcare providers and the public about the risk factors, symptoms, and complications of atypical pneumonia in the elderly. Encourage prompt medical evaluation for elderly individuals with respiratory symptoms, even if the presentation is atypical. Ensure timely access to healthcare and appropriate antibiotic therapy for elderly patients with atypical pneumonia. Optimize the management of underlying comorbidities to minimize their impact on the course of atypical pneumonia. Provide supportive care measures, such as oxygen therapy and mechanical ventilation, as needed to manage complications and support respiratory function.<sup>18-20</sup>

## 5. Conclusion

In conclusion, this meta-analysis has illuminated the critical factors influencing the severity, treatment outcomes, and mortality of atypical pneumonia in the elderly. Advanced age, comorbidities, and delayed antibiotic treatment emerged as significant risk factors for severe disease and mortality. These findings underscore the importance of early recognition, prompt treatment, and careful monitoring in this vulnerable population. Our analysis also highlights the superiority of macrolides over fluoroquinolones in treating atypical pneumonia in the elderly. Macrolides demonstrated significantly higher clinical cure rates and shorter hospital stays, making them a preferred choice for this population. However,

antibiotic selection should always be individualized based on patient-specific factors, including pathogen susceptibility, comorbidities, and potential drug interactions. The significant mortality rate associated with atypical pneumonia in the elderly demands a deeper understanding of the interplay between patient factors, pathogen characteristics, and healthcare delivery. Further research is needed to explore strategies to improve early diagnosis, optimize treatment, and ultimately reduce mortality in this vulnerable population. This meta-analysis provides valuable insights to guide clinical practice and public health interventions. By recognizing risk factors, optimizing treatment strategies, and promoting early interventions, we can strive to improve outcomes and reduce the burden of atypical pneumonia in the elderly.

## 6. References

1. Alejandro MH, Perez Laura P. Empyema caused by streptococcus constellatus: Atypical presentation of a typical pneumonia. *J Clin Case Rep.* 2018; 08(02).
2. Dorairaj A, Kopula SS, Kumar K. Atypical pneumonia - screening in a tertiary care centre. *J Clin Diagn Res.* 2015; 9(11): DC18-20.
3. Wang Z, Ji Y, Zhang J, Su K, Fan H-B, Yang W-W, et al. Investigation on atypical pathogens related with community acquired pneumonia and the factors associated with *Mycoplasma pneumoniae* infection in jiangsu, China. *Clin Lab.* 2020; 66(6).
4. Jung YJ, Yoon JL, Kim HS, Lee A-Y, Kim MY, Cho JJ. Atypical clinical presentation of geriatric syndrome in elderly patients with pneumonia or coronary artery disease. *Ann Geriatr Med Res.* 2017; 21(4): 158-63.
5. Yoshimatsu Y, Thomas H, Thompson T, Smithard DG. Prognostic factors of poor outcomes in pneumonia in older adults: aspiration or frailty? *Eur Geriatr Med.* 2024; 15(2): 481-8.

6. Hunold KM, Schwaderer AL, Exline M, Hebert C, Lampert BC, Southerland LT, et al. Functional decline in older adults with suspected pneumonia at emergency department presentation. *J Am Geriatr Soc.* 2024; 72(5): 1532–5.
7. Pandolfi MM, Wang Y, Spenard A, Johnson F, Bonner A, Ho S-Y, et al. Associations between nursing home performance and hospital 30-day readmissions for acute myocardial infarction, heart failure and pneumonia at the healthcare community level in the United States. *Int J Older People Nurs.* 2017; 12(4): e12154.
8. Goto A, Umeki K, Hiramatsu K, Kadota J-I, Komiya K. Factors associated with readmission for community-onset pneumonia among older people: a retrospective study. *Respir Investig.* 2024; 62(5): 739–43.
9. Liu M-L, Jiang H-F, Zhang X-L, Lu C-X. Risk factors analysis and prediction model construction for severe pneumonia in older adult patients. *Front Public Health.* 2024; 12: 1399470.
10. Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ito T. Aspiration pneumonia was the most frequent cause of death in older patients with SARS-CoV-2 omicron-related pneumonia in Japan. *J Am Geriatr Soc.* 2024; 72(7): 2234–6.
11. Yang Y, Zhong Y. Impact of frailty on pneumonia outcomes in older patients: a systematic review and meta-analysis. *Eur Geriatr Med.* 2024; 15(4): 881–91.
12. O’Keeffe ST. The challenge of making better decisions about oral intake in older people with “aspiration pneumonia.” *Eur Geriatr Med.* 2024; 15(4): 877–9.
13. Takazono T, Namie H, Nagayoshi Y, Imamura Y, Ito Y, Sumiyoshi M, et al. Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients. *Respirology.* 2024; 29(8): 722–30.
14. Zhang M, Dong C, Jiang Y, Guo F, Cui K, Zhang S, et al. Low thoracic skeletal muscle is a risk factor for 6-month mortality of severe community-acquired pneumonia in older men in intensive care unit. *BMC Pulm Med.* 2024; 24(1): 387.
15. Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Insights into COVID-19 pneumonia among older adults: Understanding aspiration and risk factors for mortality. *J Am Geriatr Soc.* 2024; 72(8): 2613–4.
16. Kitaw TA, Azmeraw M, Temesgen D, Haile RN. Time to recovery from severe community-acquired pneumonia and its determinants among older adults admitted to North Wollo hospitals: a multi-centred cohort study. *J Glob Health.* 2024; 14: 04203.
17. Yamaguchi K, Miyagami T, Imada R, Yanagida R, Kushiro S, Morikawa T, et al. Effect of pre-hospital living setting on nutritional intake route upon discharge in older adults with aspiration pneumonia: a prospective cohort study. *BMC Geriatr.* 2025; 25(1).
18. Yamaguchi K, Miyagami T, Imada R, Yanagida R, Kushiro S, Morikawa T, et al. Effect of pre-hospital living setting on nutritional intake route upon discharge in older adults with aspiration pneumonia: a prospective cohort study. *BMC Geriatr.* 2025; 25(1).
19. Liao J, Xie C, Shen X, Miao L. Predicting delirium in older adults with community-acquired pneumonia: a retrospective analysis of stress hyperglycemia ratio and its interactions with nutrition and inflammation. *Arch Gerontol Geriatr.* 2025; 129(105658): 105658.
20. Khan SHU, Fehaidi AAA, Akram W, Badarudeen I, Refaee MA, Kunnunmal N, et al. Study of predictors of mortality among older residents with pneumonia in Qatar’s long-term care facilities. *Aging Health Res.* 2025; 5(1): 100216.